KAYE
Kaye has been a leader for over 60 years in the Validation and Monitoring of critical process data. With its introduction of the Kaye Log -80 Vaccine Temperature Logger and KayeTrack Cloud Kaye has applied the same quality principles to ensure the validation and safety of the Cold Chain. This NFC Logger with external probe allows the precise recording and monitoring of products that are using Dry Ice pellets for Cold Chain shipment and storage. Shipments of vaccines and plasma at -70°C (-94°F) are very sensitive for breaking of the container seal, which will quickly allow the internal temperatures to rise to a critical level.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005380/en/
Drugs, vaccines, blood and biological materials are extremely sensitive to temperature variations. They must be kept and transported within a controlled temperature range during storage and transit; these are well known facts. However, during the recent fight against the COVID-19 Pandemic and with vaccines on the horizon, the demand for 24/7 temperature monitoring within the Cold Chain received another requirement, ultra-low measurements down to -70C. Besides the technology of monitoring at ultra-cold temperatures, the requirement of fast access to the temperature data without disturbing the integrity of the packaging, is foremost. Any removal of the logging device from the package, use of USB and local software applications will impede the process flow. Threshold LEDS allow the recipient to quickly see if the threshold limits have been breached, and with a quick swipe of an NFC device, all data is loaded to a local smart phone application and to the KayeTrack cloud, with corresponding email alerts, emailed PDF reports and GPS location information.
The Kaye Log -80 Vaccine Temperature Logger is an extension of Kaye’s Cold Chain solutions. From Thermal Validation, Continuous Monitoring, and Cold Chain Loggers, Kaye is committed to providing accurate, reliable, secure data and systems to help ensure the quality of all Pharma/Biotech products.
For information on the product, please visit https://www.kayeinstruments.com/kaye-log-80-vaccine-temperature-logger
About Kaye
For more than sixty years, Kaye has been at the forefront of high accuracy process measurement, for applications from thermal process validation and environmental and cold chain monitoring, to sensor calibration. https://www.kayeinstruments.com
Kaye is a subsidiary of Amphenol Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005380/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Posiflex to Showcase AI-Powered Retail Innovation at EuroShop 202619.1.2026 09:57:00 CET | Press release
From AI-powered self-checkout to next-generation Tap-to-Pay transactions, Posiflex presents end-to-end solutions that redefine the modern retail journey Posiflex Technology, Inc., a global leader in Point of Sale (POS) systems and Online-to-Offline (O2O) solutions, will present its latest portfolio of AI-powered retail innovations at EuroShop 2026, taking place from February 22 to 26, 2026 at Messe Düsseldorf, Germany. Celebrating the 60th edition of the world’s leading retail trade fair, Posiflex will demonstrate how AI-enabled technologies and scenario-driven system design can address the evolving demands of modern retail environments, spanning self-checkout, AI recognition, contactless transactions, kitchen operations, and next-generation self-service. Visitors are invited to explore these solutions at Hall 6, Booth C42, and discover how Posiflex supports retailers in building agile, future-ready business models. This press release features multimedia. View the full release here: ht
Alta Semper Signs Definitive Agreements to Acquire a Majority Stake in Nature’s Rule, a MENA-Focused Leader in Dietary Supplements and Sports Nutrition19.1.2026 09:13:00 CET | Press release
Alta Semper, a London-based private equity firm focused on healthcare and consumer investments across growth markets, today announced that it has signed definitive agreements to acquire a majority stake in Nature’s Rule, a leading sports nutrition and dietary supplements company headquartered in the UAE, with an established manufacturing presence in Egypt. The acquisition is a majority investment in Prowell Holding, the parent company of Nature’s Rule, the operator of the largest fully dedicated sports nutrition and dietary supplements manufacturing facility in MENA. The company’s infrastructure and in-house R&D capabilities support a portfolio of private-label clients and proprietary brands, including Redrex, its flagship, market-leading sports nutrition brand developed in collaboration with global bodybuilding icon Mamdouh Elssbiay (“Big Ramy”). The founders will retain a significant stake and continue to lead the business. The partnership will execute a focused value-creation plan t
The UK Chooses Bridge Over Troubled Water as the Nation’s Favourite Song of Hope in Solidarity With Refugees19.1.2026 09:00:00 CET | Press release
Simon and Garfunkel classic named the UK’s top #HopeHitOver 1000 people from across the country nominated songs to show their solidarity with refugees around the world this winterThe most popular Hope Hits available on the Hope On Repeat playlist to get you through Blue Monday Simon and Garfunkel’s Bridge Over Troubled Water has been votedas the UK’s number one #HopeHit ― as part of UK for UNHCR’s ‘Hope on Repeat’ campaign, raising awareness of the hardships facing refugees across the globe this winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119165712/en/ Simon & Garfunkel's Bridge Over Troubled Water voted the UK's number one #HopeHit With 10% of the public vote, Bridge Over Troubled Water emerged as the UK’s most popular #HopeHit. Since November, the UN Refugee Agency’s national charity partner has invited people to nominate their #HopeHits - the tunes that connect us and warm our hearts as the weather gets cold
Prodalim Expands SOLOS Capabilities with New Dealcoholization Site in Spain19.1.2026 08:33:00 CET | Press release
Prodalim, a global leader in juice and specialty ingredients solutions, announced today the expansion of its SOLOS division with the opening of a dedicated dealcoholization and aroma recovery site in Valencia, Spain. The new facility is fully operational and strengthens Prodalim’s ability to support the rapidly growing no- and low-alcohol (NoLo) beverage market across Europe. During the coming months, an additional SOLOS site in California is planned to be inaugurated, further expanding overall capacity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260118626123/en/ Inauguration of the SOLOS Valencia Site for Advanced NoLo Solutions The global NoLo category continues to expand, driven by consumer demand for mindful drinking and healthier lifestyle choices. Industry forecasts estimate the NoLo global market at approximately USD 25 billion in 2025, with expected annual growth of 8–10% as the category expands across beers, win
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer19.1.2026 08:30:00 CET | Press release
Based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s ENHERTU in combination with pertuzumab significantly improved progression-free survival versus current first-line standard of care in HER2 positive metastatic breast cancer The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom